共 50 条
- [31] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S3 - S3Louis, EdouardPanaccione, RemoParkes, GarethPevrin-Biroulet, LaurentFerrante, MarcTakeuchi, KenSiegmund, BrittaLevine, PhillipKalabic, JasminaNeimark, EzequielWallace, KoriChen, SuDuan, W. RachelArmuzzi, AlessandroBiedermann, LucLoftus, EdwardMelmed, GilSchreiber, Stefan
- [32] Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitisJOURNAL OF CROHNS & COLITIS, 2019, 13 : S59 - S60Sandborn, W. J.Sands, B.Kobayashi, T.Tuttle, J.Schmitz, J.Durante, M.Higgs, R.Canavan, J. B.Siegel, R.Ferrante, M.
- [33] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDYGASTROENTEROLOGY, 2023, 164 (06) : S1572 - S1572Allegretti, Jessica R.Peyrin-Biroulet, LaurentFeagan, Brian G.Bressler, BrianLichtenstein, Gary R.Huang, Kuan-Hsiang G.Germinaro, MatthewShipitofsky, NicoleJiang, LingjingZhang, HongyanHisamatsu, TadakazuPanes, JulianDignass, AxelSands, Bruce E.Rubin, David T.
- [34] Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)JOURNAL OF CROHNS & COLITIS, 2023, 17 : 644 - 646Panaccione, R.Lichtenstein, G.Nakase, H.Armuzzi, A.Kucharzik, T.Levy, G.Palac, H.Kujawski, M.Klaff, J.Cheon, J. H.
- [35] SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)GASTROENTEROLOGY, 2023, 164 (06) : S1100 - S1100Panaccione, RemoLichtenstein, Gary R.Nakase, HiroshiArmuzzi, AlessandroKucharzik, TorstenLevy, GwenethPalac, HannahKujawski, MichelleKlaff, JustinCheon, Jae Hee
- [36] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trialJOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54Sandborn, W. J.Ferrante, M.Bhandari, B. R.Berliba, E.Hibi, T.D'Haens, G. Geert R.Tuttle, J.Krueger, K.Friedrich, S.Durante, M.Arora, V.Feagan, B.
- [37] EXTENDED TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 2 TRIALGASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1094Sandborn, William J.Ferrante, MarcBhandari, Bal R.Berliba, ElinaHibi, ToshifumiD'Haens, Geert R.Tuttle, JayKrueger, Kathryn A.Friedrich, StuartDurante, MichaelArora, VipinFeagan, Brian G.
- [38] A Multi-Center Open-Label Study Assessing Pharmacokinetics, Efficacy, and Safety of Subcutaneous Golimumab in Pediatric Patients With Moderately-Severely Active Ulcerative ColitisGASTROENTEROLOGY, 2016, 150 (04) : S132 - S132Hyams, Jeffrey S.Griffiths, Anne M.Veereman, GigiTurner, DanChan, DaphneAdedokun, Omoniyi J.Padgett, LakshmiStrauss, Rick
- [39] A Multicenter Open-Label Study Assessing Pharmacokinetics, Efficacy, and Safety of Subcutaneous Golimumab in Pediatric Subjects with Moderately-Severely Active Ulcerative ColitisINFLAMMATORY BOWEL DISEASES, 2016, 22 : S39 - S40Hyams, JeffreyGriffiths, AnneVeereman, GenevieveTurner, DanChan, DaphneAdedokun, OmoniyiDamaraju, LakshmiStrauss, Richard
- [40] EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDYGASTROENTEROLOGY, 2021, 160 (06) : S125 - S125Feagan, Brian G.Loftus, Edward V.Danese, SilvioVermeire, SeverineSandborn, William J.Ritter, Timothy E.Mehta, RajivSeidler, UrsulaSeibold, FrankBeales, IanKim, Hyo JongMcNally, JohnYun, ChoheeZhao, SallyLiu, XiaopengTasset, Chantal T.Besuyen, RobinWatanabe, MamoruSchreiber, StefanRogler, GerhardHibi, ToshifumiPeyrin-Biroulet, Laurent